The funding was backed by the UK Innovation & Science Seed Fund, Oxford Innovation EIS Growth Fund, Oxford Innovation Finance's Angel Network, and the Defence and Security Accelerator.
"This new investment provides us with the funding to take our game changing technology to commercialisation, helping deliver the UK government’s semiconductor and technology strategy. Our Inertial sensors are already gaining strong industry interest globally with a major aerospace and defence contractor having already placed contracts. Our revolutionary gravity sensor will be commercialised later this year with the industry interest shown by our acceptance on to Europe’s largest infrastructure accelerator program and the award of funding from the Department for Business and Trade railway construction innovation competition. We are very excited for this next stage in SMG’s journey."
— Francis Neill, Chief Executive Officer and Director
The seed round was led by the UK Innovation & Science Seed Fund to support team expansion and product development.
"X-ray scanners are such a common technology that we don’t often think of them as an area for innovation. But the reality is that the addressable market is huge – far beyond the obvious medical applications, with X-ray equipment critical in a range of sectors from construction to manufacturing. Silveray’s technology could play a key role in bringing the world’s oldest imaging technology into the 21st century."
Science Angel Syndicate backed the funding round alongside a broad group of institutional and angel investors.
"I've long been fascinated by how reversing mitochondrial dysfunction could arrest the progression of degenerative diseases, which place great burdens on patients and healthcare systems. This seed financing will enable us to advance MitoRx's first-in-class therapeutic pipeline. We are the first biotech to address dysfunction of sulfide-signalling, a fundamental part of life's energy systems. I'm also delighted to welcome Glyn to the team whose wealth of experience will be a great asset as we accelerate our novel pipeline of small molecule mitochondrial protective therapeutics towards the clinic."
The seed round was led by UKI2S and Longwall Ventures to support cell therapy bioprocessing development.
"We are thrilled to close this initial funding round with help from UKI2S. We are continuing to establish partnerships with Biotech and Pharma, on top of our existing partnerships with the Cell and Gene Therapy Catapult and the Centre for Process Innovation. The funding will be used to further develop our technology, as well as fund trials with our partners."
The funding round was led by UK Innovation & Science Seed Fund with participation from LifeArc and Parkwalk.
"The increasing incidence of debilitating ophthalmic diseases brings morbidity and economic cost, and we are pleased to announce our seed funding today to tackle these urgent issues. We thank our investors UKI2S, LifeArc and Parkwalk for their support, and look forward to working with them to build Ikarovec into a leading gene therapy company."
